Related Experiment Video

Updated: Jan 19, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.1K

Effect of Synbiotic on the Treatment of Jaundice in Full Term Neonates: A Randomized Clinical Trial

Shokoufeh Ahmadipour1,2, Parastoo Baharvand3, Parisa Rahmani4

  • 1Razi Herbal Medicine Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.

Pediatric Gastroenterology, Hepatology & Nutrition
|September 27, 2019
PubMed

Insights

Synbiotics significantly reduced hyperbilirubinemia in full-term neonates receiving phototherapy. This adjuvant therapy shortened hospital stays by increasing stool and urine output.

Area of Science:

  • Neonatal Medicine
  • Gastroenterology
  • Microbiology

Background:

  • Neonatal jaundice is a common cause of hospital admission.
  • Phototherapy is standard treatment, but auxiliary methods are sought to improve outcomes.
  • Hyperbilirubinemia management in newborns requires effective and safe interventions.

Purpose of the Study:

  • To evaluate the efficacy of synbiotics as an adjunctive treatment for hyperbilirubinemia in full-term neonates.
  • To determine the impact of synbiotics on serum bilirubin levels and clinical parameters.
  • To assess the effect of synbiotics on hospitalization duration in jaundiced neonates.

Main Methods:

  • Randomized clinical trial involving 83 full-term neonates.
  • Participants received standard phototherapy; the synbiotic group (n=40) also received daily synbiotics.
  • Serum bilirubin, urine/stool output, feeding, and weight were monitored daily.

Main Results:

  • The synbiotic group exhibited lower mean total serum bilirubin levels compared to the control group.
  • Significantly higher urine and stool frequency was observed in the synbiotic group.
  • The duration of hospitalization was shorter in neonates treated with synbiotics.

Conclusions:

  • Synbiotics demonstrate a significant therapeutic effect as adjuvant therapy for neonatal jaundice.
  • This intervention may help reduce hospitalization duration in full-term neonates with hyperbilirubinemia.
  • Further research with larger cohorts and extended follow-up is recommended to validate routine synbiotic use.
Abstract

Keywords:
Hyper-bilirubinemiaJaundiceNeonate infantPhototherapyProbioticsSynbiotics

More Related Videos

Probiotic Studies in Neonatal Mice Using Gavage10:36

Probiotic Studies in Neonatal Mice Using Gavage

Published on: January 27, 2019

20.6K
Isolation of Neonatal Extrahepatic Cholangiocytes07:54

Isolation of Neonatal Extrahepatic Cholangiocytes

Published on: June 5, 2014

10.8K

Related Concept Videos

Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
144
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
644
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
506
Bioavailability Study Design: Absolute Versus Relative Bioavailability01:27

Bioavailability Study Design: Absolute Versus Relative Bioavailability

Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
304
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
195